Zynrelef Approved to Treat Postoperative Pain for Up to 72 Hours
The needle-free product is intended for single-dose administration only.
Pain Management
NSAID Use Not Linked to Increased Mortality, Severity in COVID-19
In propensity score-matched cohort, no increase seen in in-hospital mortality, critical care admission, requirement for ventilation
Depot Buprenorphine Improves Outcomes in Opioid Dependence
Improvement seen in treatment satisfaction and several secondary end points for depot buprenorphine vs sublingual buprenorphine
Study: Ibuprofen Found Safest NSAID for the Kidney
In a study comparing the effect of 9 oral nonsteroidal anti-inflammatory drugs on kidney function, ibuprofen conferred the lowest risk for incident eGFR less than 60 mL/min/1.73 m2 and an eGFR decline of 30% or greater.
Combination Treatment Appears Beneficial for Chronic Migraine
Data analysis revealed that CGRP mAbs were discontinued more frequently than onabotulinumtoxinA (23% vs 3%).
Kloxxado, a Higher Dose Naloxone Nasal Spray, Gets FDA Approval
Kloxxado is intended for immediate administration as emergency therapy in settings where opioids may be present.
Supply Steady for Existing Patients Receiving Opioids During COVID-19
Opioid prescriptions for opioid-naive decreased then rebounded, while buprenorphine initiation remained lower
Peripheral Nerve Stimulation May Cut Pain After Orthopedic Surgery
Pain scores, opioid consumption reduced in first postoperative week with percutaneous peripheral nerve stimulation versus sham treatment
HHS Issues Guidelines Expanding Access to Buprenorphine Treatment
Eligible practitioners who are registered to prescribe controlled substances are exempt from certain statutory certification requirements
Prevalence of Chronic Pain 20.5% in United States
Most common pain locations were back and hip, knee, or foot; physical therapy and massage most often used for management
